Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Contrast-enhanced MRI with gadoquatrane vs macrocyclic GBCAs in non-CNS pathology
2022-501885-24-00Phase 3Completed
- Sponsor
- Bayer
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of gadoquatrane in non-central nervous system pathology requiring contrast-enhanced mri (2 arms), sponsored by Bayer. Started Aug 2023; status: completed.
02
Drugs
gadoquatrane
03
Conditions
non-central nervous system pathology requiring contrast-enhanced mri
Beyond the preview
Go deeper on 2022-501885-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501885-24-00.